[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100617023":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":10,"responsibleParty":26,"collaborators":10,"id":28,"slug":29,"hasResults":30,"nctId":31,"briefTitle":32,"officialTitle":33,"acronym":34,"eligibilityCriteria":35,"healthyVolunteers":30,"sex":36,"minAge":37,"maxAge":38,"enrollmentInfo":39,"targetDuration":10,"studyType":42,"phases":10,"briefSummary":43,"conditions":44,"keywords":47,"overallStatus":50,"whyStopped":10,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":10},{"fullName":5,"class":6},"First Affiliated Hospital of Ningbo University","NETWORK",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"PFA after LAAO group",null,"The patients in this group have previously undergone Left Atrial Appendage Occlusion (LAAO) surgery and are scheduled to undergo Pulsed Field Ablation (PFA). The study will only collect comprehensive data throughout their treatment process without introducing any additional interventions.",[13],"Procedure: Pulsed Field Ablation",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"PROCEDURE","Pulsed Field Ablation","Pulsed Field Ablation is a surgical technique for atrial fibrillation ablation that uses pulsed electric fields.",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Jiedong Zhou, PhD","CONTACT","17816533346","1552882461@qq.com",{"type":27,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100617023","pulsed-field-ablation-for-non-valvular-atrial-fibrillation-after-left-atrial-appendage-occlusion-100617023",false,"NCT07313228","Pulsed Field Ablation for Non-valvular Atrial Fibrillation After Left Atrial Appendage Occlusion","Pulsed Field Ablation of Non-valvular Atrial Fibrillation After Left Atrial Appendage Occlusion: A Prospective, Single-center, Single-arm Clinical Trial","PFA after LAAO","Inclusion Criteria:\n\n1. Aged 18-75 years;\n2. Documented symptomatic atrial fibrillation;\n3. Ineffective or intolerant to at least one class I or III antiarrhythmic drug;\n4. Able to fully understand the treatment protocol, voluntarily sign the informed consent form, and willing to undergo the required examinations, procedures, and follow-up.\n\nExclusion Criteria:\n\n1. Patients who have previously undergone left atrial surgery;\n2. Left atrial thrombus;\n3. Patients with pulmonary agenesis;\n4. Female patients of reproductive age who cannot use effective contraception within 12 months after enrollment;\n5. Left atrial anteroposterior diameter ≥ 55 mm;\n6. Left ventricular ejection fraction (LVEF) ≤ 40%;\n7. Patients who have previously undergone interatrial septal repair or removal of atrial myxoma;\n8. Patients with active implanted devices (e.g., pacemaker, ICD);\n9. Patients with NYHA heart failure class III-IV;\n10. Patients with a clear history of cerebrovascular disease (including cerebral hemorrhage, stroke, or TIA) within the past 6 months;\n11. Patients who have experienced cardiovascular events (e.g., acute myocardial infarction, coronary intervention or bypass surgery, valve replacement or repair, atrial or ventricular surgery) within the past 3 months;\n12. Patients with acute or severe systemic infections;\n13. Patients with severe liver or kidney disease, malignancy, or end-stage disease that may affect the treatment, assessment, or compliance of the trial (as judged by the investigator);\n14. Patients with significant bleeding tendency, hypercoagulable state, or severe hematologic disorders;\n15. Patients who have participated or are currently participating in another clinical trial within the past 12 months prior to enrollment;\n16. Patients who the investigator deems unsuitable for participation in this trial.","ALL","18 Years","75 Years",{"count":40,"type":41},70,"ESTIMATED","OBSERVATIONAL","This is a single-center, prospective, single-arm clinical trial designed to evaluate the safety and efficacy of pulsed field ablation (PFA) after left atrial appendage occlusion (LAAO) in patients with non-valvular atrial fibrillation (AF). The trial will include patients who have undergone successful LAAO and have symptomatic AF that is refractory to or intolerant of class I or III antiarrhythmic drugs. The primary objective is to assess the effectiveness of PFA in preventing AF recurrence and its safety, including the occurrence of serious adverse events. Patients will be followed up for 12 months post-procedure to evaluate outcomes such as recurrence of AF, complications, and device-related issues.",[45,46,17],"Atrial Fibrillation","Left Atrial Appendage Occlusion",[45,48,49],"left atrial appendage occlusion","pulsed field ablation","NOT_YET_RECRUITING","2025-12-17",{"date":53,"type":54},"2025-12-31","ACTUAL",{"date":56,"type":41},"2025-12",{"date":58,"type":41},"2027-06",{"name":5,"class":6}]